vs
Side-by-side financial comparison of ACV Auctions Inc. (ACVA) and ADMA BIOLOGICS, INC. (ADMA). Click either name above to swap in a different company.
ACV Auctions Inc. is the larger business by last-quarter revenue ($183.6M vs $139.2M, roughly 1.3× ADMA BIOLOGICS, INC.). On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 15.1%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $-14.7M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 12.3%).
ACV Auctions Inc.ACVAEarnings & Financial Report
ACV Auctions Inc. operates a leading digital wholesale vehicle auction platform serving automotive dealers across the U.S. and Canada. It offers end-to-end services including transparent vehicle inspections, secure payment processing, and logistics support, enabling efficient trading of used vehicles between registered wholesale buyers and sellers.
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
ACVA vs ADMA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.6M | $139.2M |
| Net Profit | — | $49.4M |
| Gross Margin | — | 63.8% |
| Operating Margin | -9.7% | 45.1% |
| Net Margin | — | 35.5% |
| Revenue YoY | 15.1% | 18.4% |
| Net Profit YoY | — | -55.9% |
| EPS (diluted) | $-0.12 | $0.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.6M | $139.2M | ||
| Q3 25 | $199.6M | $134.2M | ||
| Q2 25 | $193.7M | $122.0M | ||
| Q1 25 | $182.7M | $114.8M | ||
| Q4 24 | $159.5M | $117.5M | ||
| Q3 24 | $171.3M | $119.8M | ||
| Q2 24 | $160.6M | $107.2M | ||
| Q1 24 | $145.7M | $81.9M |
| Q4 25 | — | $49.4M | ||
| Q3 25 | $-24.5M | $36.4M | ||
| Q2 25 | $-7.3M | $34.2M | ||
| Q1 25 | $-14.8M | $26.9M | ||
| Q4 24 | — | $111.9M | ||
| Q3 24 | $-16.0M | $35.9M | ||
| Q2 24 | $-17.1M | $32.1M | ||
| Q1 24 | $-20.5M | $17.8M |
| Q4 25 | — | 63.8% | ||
| Q3 25 | — | 56.3% | ||
| Q2 25 | — | 55.1% | ||
| Q1 25 | — | 53.2% | ||
| Q4 24 | — | 53.9% | ||
| Q3 24 | — | 49.8% | ||
| Q2 24 | — | 53.6% | ||
| Q1 24 | — | 47.8% |
| Q4 25 | -9.7% | 45.1% | ||
| Q3 25 | -11.9% | 38.0% | ||
| Q2 25 | -3.7% | 35.1% | ||
| Q1 25 | -7.9% | 30.4% | ||
| Q4 24 | -16.2% | 32.6% | ||
| Q3 24 | -10.0% | 33.1% | ||
| Q2 24 | -11.6% | 36.6% | ||
| Q1 24 | -15.5% | 26.7% |
| Q4 25 | — | 35.5% | ||
| Q3 25 | -12.3% | 27.1% | ||
| Q2 25 | -3.8% | 28.1% | ||
| Q1 25 | -8.1% | 23.4% | ||
| Q4 24 | — | 95.2% | ||
| Q3 24 | -9.4% | 30.0% | ||
| Q2 24 | -10.6% | 29.9% | ||
| Q1 24 | -14.1% | 21.7% |
| Q4 25 | $-0.12 | $0.20 | ||
| Q3 25 | $-0.14 | $0.15 | ||
| Q2 25 | $-0.04 | $0.14 | ||
| Q1 25 | $-0.09 | $0.11 | ||
| Q4 24 | $-0.15 | $0.45 | ||
| Q3 24 | $-0.10 | $0.15 | ||
| Q2 24 | $-0.10 | $0.13 | ||
| Q1 24 | $-0.13 | $0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $271.5M | $87.6M |
| Total DebtLower is stronger | — | $72.1M |
| Stockholders' EquityBook value | $429.7M | $477.3M |
| Total Assets | $1.1B | $624.2M |
| Debt / EquityLower = less leverage | — | 0.15× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $271.5M | $87.6M | ||
| Q3 25 | $265.3M | $61.4M | ||
| Q2 25 | $258.4M | $90.3M | ||
| Q1 25 | $291.9M | $71.6M | ||
| Q4 24 | $224.1M | $103.1M | ||
| Q3 24 | $252.5M | $86.7M | ||
| Q2 24 | $215.0M | $88.2M | ||
| Q1 24 | $209.8M | $45.3M |
| Q4 25 | — | $72.1M | ||
| Q3 25 | — | $72.4M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $72.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $429.7M | $477.3M | ||
| Q3 25 | $434.4M | $431.2M | ||
| Q2 25 | $448.8M | $398.3M | ||
| Q1 25 | $439.6M | $373.4M | ||
| Q4 24 | $440.0M | $349.0M | ||
| Q3 24 | $456.2M | $231.9M | ||
| Q2 24 | $457.6M | $188.3M | ||
| Q1 24 | $458.3M | $153.7M |
| Q4 25 | $1.1B | $624.2M | ||
| Q3 25 | $1.2B | $568.7M | ||
| Q2 25 | $1.1B | $558.4M | ||
| Q1 25 | $1.2B | $510.6M | ||
| Q4 24 | $984.1M | $488.7M | ||
| Q3 24 | $1.0B | $390.6M | ||
| Q2 24 | $1.0B | $376.4M | ||
| Q1 24 | $1.0B | $350.9M |
| Q4 25 | — | 0.15× | ||
| Q3 25 | — | 0.17× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.21× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-12.4M | $35.6M |
| Free Cash FlowOCF − Capex | $-14.7M | $34.6M |
| FCF MarginFCF / Revenue | -8.0% | 24.8% |
| Capex IntensityCapex / Revenue | 1.2% | 0.8% |
| Cash ConversionOCF / Net Profit | — | 0.72× |
| TTM Free Cash FlowTrailing 4 quarters | $69.1M | $27.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-12.4M | $35.6M | ||
| Q3 25 | $10.3M | $13.3M | ||
| Q2 25 | $13.7M | $21.1M | ||
| Q1 25 | $66.6M | $-19.7M | ||
| Q4 24 | $-3.2M | $50.2M | ||
| Q3 24 | $21.1M | $25.0M | ||
| Q2 24 | $4.5M | $45.6M | ||
| Q1 24 | $43.0M | $-2.2M |
| Q4 25 | $-14.7M | $34.6M | ||
| Q3 25 | $7.7M | $-1.1M | ||
| Q2 25 | $10.9M | $18.7M | ||
| Q1 25 | $65.3M | $-24.4M | ||
| Q4 24 | $-3.9M | $47.5M | ||
| Q3 24 | $20.2M | $24.0M | ||
| Q2 24 | $2.7M | $43.6M | ||
| Q1 24 | $41.9M | $-4.6M |
| Q4 25 | -8.0% | 24.8% | ||
| Q3 25 | 3.8% | -0.8% | ||
| Q2 25 | 5.6% | 15.3% | ||
| Q1 25 | 35.7% | -21.2% | ||
| Q4 24 | -2.5% | 40.4% | ||
| Q3 24 | 11.8% | 20.0% | ||
| Q2 24 | 1.7% | 40.7% | ||
| Q1 24 | 28.8% | -5.6% |
| Q4 25 | 1.2% | 0.8% | ||
| Q3 25 | 1.3% | 10.7% | ||
| Q2 25 | 1.5% | 2.0% | ||
| Q1 25 | 0.7% | 4.1% | ||
| Q4 24 | 0.4% | 2.3% | ||
| Q3 24 | 0.6% | 0.9% | ||
| Q2 24 | 1.1% | 1.9% | ||
| Q1 24 | 0.7% | 2.9% |
| Q4 25 | — | 0.72× | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.62× | ||
| Q1 25 | — | -0.73× | ||
| Q4 24 | — | 0.45× | ||
| Q3 24 | — | 0.70× | ||
| Q2 24 | — | 1.42× | ||
| Q1 24 | — | -0.12× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACVA
| Auction Marketplace Revenue | $77.6M | 42% |
| Other Marketplace Revenue | $72.4M | 39% |
| Customer Assurance | $24.1M | 13% |
| Data Services Revenue | $9.4M | 5% |
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
